Apple Faces Sales Halt for Apple Watch Series 9 and Ultra 2

Due to a legal dispute over a patent related to the blood oxygen monitoring feature in the Apple Watch Series 9 and Ultra 2, Apple has decided to temporarily cease sales of these products. This decision follows a ruling by the U.S. International Trade Commission (ITC) against Apple for the unauthorized use of blood oxygen technology from medical tech company Masimo. The halt in sales will take effect from December 21 online and from December 24 in retail stores. Apple has expressed strong disagreement with the ruling and is actively exploring various legal and technical avenues to address the situation and ensure continued availability of the Apple Watch to its customers. The blood oxygen monitor is a vital feature that allows users to measure oxygen levels in their blood, a crucial health metric. As the dispute undergoes a presidential review, Apple is taking proactive steps to adhere to the ITC's order. The company's stance reflects its commitment to resolving the issue and maintaining the availability of its products.